Company Filing History:
4 out of 2,928 
1 out of 1,732 
Years Active: 2010-2023
Title: Clive Henry Wasserfall: Innovator in Diabetes Diagnosis and Immune Modulation
Introduction
Clive Henry Wasserfall is a notable inventor based in Gainesville, FL (US), recognized for his contributions to the fields of diabetes diagnosis and immune response modulation. With a total of four patents to his name, Wasserfall has made significant strides in medical research, particularly concerning type 1 diabetes.
Latest Patents
Wasserfall's latest patents include innovative methods for the diagnosis of type 1 diabetes. His research identifies seventeen antigens as potential biomarkers for early detection and risk prediction of type 1 diabetes (T1D). These antigens include MLH1, MTIF3, PPIL2, NUP50, TOX4, FIGN, C9orf142, ZNF280D, HES1, QRFPR, CTRC, SNX6, SYTL4, ELA2A, IGRP, PAX6, and HMGN3. Additionally, he has developed materials and methods for modulating immune responses, which can be utilized to prevent and treat pathogenic infections, cancer, allergenic reactions, and unwanted immune or autoimmune responses.
Career Highlights
Throughout his career, Wasserfall has worked with esteemed institutions such as the University of Florida Research Foundation and Arizona State University. His work has been pivotal in advancing the understanding of immune responses and their implications in various diseases.
Collaborations
Wasserfall has collaborated with notable colleagues, including Mark A. Atkinson and Tamir M. Ellis, contributing to a rich exchange of ideas and research in his field.
Conclusion
Clive Henry Wasserfall's innovative work in diabetes diagnosis and immune modulation highlights his significant impact on medical research. His contributions continue to pave the way for advancements in understanding and treating complex health conditions.